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Abstract 
The aim of this study is to assess the quality of Valzan
® tablet (160 mg, 
valsartan immediate release test formulation) by comparing its pharmacokinetic 
parameters with Diovan
® tablet (160 mg, valsartan reference formulation). 
Valzan
® tablets were prepared according to a dry granulation method (roll 
compaction). To assess the bioequivalence of Valzan
® tablets a randomized, 
two-way, crossover, bioequivalence study was performed in 24 healthy male 
volunteers. The selected volunteers were divided into two groups of 12 
subjects. One group was treated with the reference formulation (Diovan
®) and 
the other one with the generic Valzan
®, with a cross-over after the drug washout 
period of 14 days. Blood samples were collected at fixed time intervals and 
valsartan concentrations were determined by a validated HPLC assay method. 
The pharmacokinetic parameters AUC0–48, AUC0–∞, Cmax, Tmax, Ke and T1/2 were 
determined for both the tablets and were compared statistically to evaluate the 
bioequivalence between the two brands of valsartan, using the statistical model 
recommended by the FDA. The analysis of variance (ANOVA) did not show any 
significant difference between the two formulations and 90% confidence 
intervals (CI) fell within the acceptable range for bioequivalence. Based on this 
statistical evaluation it was concluded that the test tablets (Valzan
®) is well 
formulated, since it exhibits pharmacokinetic profile comparable to the reference 
brand Diovan
®. 124  A. N. Zaid et al.:  
Sci Pharm. 2011; 79: 123–135 
Keywords 
Valsartan • Formulation • Bioequivalence • Immediate Release • HPLC • Diovan
® • Valzan
® 
Introduction 
Valsartan is chemically N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine 
(Figure 1). 
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Fig. 1.   Chemical structure of Valsartan. 
Valsartan is a nonpeptide, orally active and specific angiotensin II antagonist acting on the 
AT1 receptor subtype present in many tissues, such as vascular smooth muscle and the 
adrenal gland [1]. Placebo-controlled trials have found valsartan to be both safe and 
effective for the treatment of hypertension [2]. With valsartan taken in a dosage of 80 to 
320 mg once daily, the mean reduction in diastolic blood pressure is 6 to 9 mm Hg, and 
the mean reduction in systolic pressure is 3 to 6 mm Hg [1]. Studies have shown that 
valsartan is as effective as enalapril, lisinopril and amlodipine in the treatment of mild to 
moderate hypertension [3–5]. Valsartan is rapidly absorbed from the gastrointestinal tract 
after oral administration and can be administered without regard to food intake [6]. The 
peak effect of valsartan is evident in 2–4 h; the bioavailability is 25%. Valsartan has a half-
life of 6–9 h and demonstrates antihypertensive effects for approximately 24 h. Less than 
10% of an orally administered dose of valsartan undergoes biotransformation in the liver; 
the enzymes responsible for its metabolism are unknown, and no active metabolites have 
been identified [7, 8]. Elimination occurs primarily in the bile (86%) and to a lesser extent 
via the kidneys (13%), largely as unchanged drug [5, 9]. This study aims to assess the 
quality of a new generic Valzan
® (160 mg valsartan tablets) with the original brand Diovan
® 
(160mg valsartan tablets) by comparing their pharmacokinetic parameters according to the 
FDA guidelines. Furthermore, the excipients and formulation method used to prepare 
Diovan
® tablets are reported in order to help future studies related to the bioclassification 
of valsartan. 
Results and Discussion 
Results of validation procedures  
Under the chromatographic conditions described, valsartan and the internal standard 
peaks were completely resolved during the run time of the assay with retention times of 
2.9 min and 4.15 min respectively (Figure 2). The broad peak from 1.5–2.3 min is related 
to plasma components that their concentration may be influenced by the presence of 
valsartan [10]. However, these components do not alter the valsartan quantitation since 
the peaks of both valsartan and the internal standard are completely resolved.   Formulation and Bioequivalence of Two Valsartan Tablets After a Single Oral Administration  125 
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Fig. 2.   Representative chromatograms for blank plasma sample (A), blank plasma 
spiked with valsartan to produce drugs concentration of 5 µg/mL and internal 
standard (B), and plasma samples that was obtained 6 h after administration of 
the test drug to volunteer # 5 T(C).  
Calibration curves constructed from the peak area ratio (valsartan/ internal standard) and 
the corresponding valsartan concentration in each calibration standard were linear from 
0.01 to 1000 μg. The mean slope and intercept for the different calibration curves of 
valsartan in human plasma are presented in Table 1.The correlation coefficient was 
always greater than 0.999 during the course of the validation. 
Tab. 1.   Mean slope and intercept for the different calibration curves of valsartan in 
human plasma. 
Calibration Curve Parameter  Mean ± SD 
Slope  1.510 ± 0.031 
Intercept  0.029 ± 0.011 
Correlation coefficient  0.999 
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The intraday coefficient of variation ranged from 0.825 to 18.18%, while the inter-day 
coefficient of variation ranged from 0.969 to 13.20% indicating that the method is precise. 
The accuracy of the method was proven since the intra-day accuracy was in the range 
from 99 to 111% and the inter-day accuracy was in the range of 98.52 to 106% during the 
entire range of the calibration curves. 
The results of stability of the drug at room temperature and in frozen plasma showed that 
valsartan is stable. In fact, the difference in the drug concentrations in the two analyses 
was always less than 10%. There was no trend in the changes in the drug concentration 
when the samples were kept at room temperature for 24  h, indicating the stability of 
valsartan in the plasma samples at room temperature. In frozen plasma, the difference in 
the drug concentration in all samples in the two analyses was always less than 10% in 
each sample. There was no trend in the change in the drug concentration in frozen plasma 
stored at −20°C during the study period, indicating the stability of valsartan in frozen 
plasma.  
The limit of quantification of valsartan in this assay was 0.01 µg/mL. The retention time of 
the drug in the standard and the study samples were identical. There were no peaks for 
endogenous compounds that appeared at the same retention time for valsartan in the 
chromatograms for six different blank plasma samples.  
The results of incurred sample reanalysis demonstrate that for each analyte the difference 
between the original and reanalyzed values was within 15% of the total samples 
reanalyzed. This confirms that the analytical procedure is valid and reproducible. 
Several HPLC methods for the determination of valsartan in human plasma were reported 
in the literature. Most of these methods employ a liquid extraction procedure with protein 
precipitation (mostly with methanol), reversed-phase C18 column separation followed by 
fluorometric [11–15] or ultraviolet detection [16, 17]. Likewise, the method described in this 
report uses a liquid extraction step followed by fluorescence detection. Our method 
provides results comparable to those obtained using flurometric detection and superior to 
those utilizing UV detection. However, our method possesses a number of advantages. 
With the chromatographic conditions described, it was possible to completely resolve 
valsartan and the internal standard (etodolac) peaks within 7 min. The quantitative range 
of the assay (0.01–1 µg/mL) is comparable to that obtained by Daneshtalab et al. [11] 
without the additional time required for the back-extraction step used by the authors. The 
method allows accurate quantification of valsartan concentrations that are expected after 
regular dose administration. Overall, our method provides a rapid, sensitive, and 
economically-convenient procedure for the analysis of valsartan in human plasma samples 
encountered in pharmacokinetics studies. 
Results of pharmacokinetic study 
The alternative HPLC-fluorescence method described and used here for valsartan 
quantification provides adequate sensitivity and high sample throughput required for 
pharmacokinetic studies. Both valsartan immediate release tablets (Valzan
® & Diovan
® 
160 mg tablet) were well tolerated at the administered dose by all the subjects and no 
unexpected incidents occurred that could have influenced the outcome of the study. All the 
volunteers discharged from the hospital after the studies were in good health. Both the   Formulation and Bioequivalence of Two Valsartan Tablets After a Single Oral Administration  127 
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medications were readily absorbed from the GI tract and it was possible to quantify the 
drug at the first sampling time in all the volunteers. Figure 3 shows mean valsartan plasma 
concentrations as a function of time after the oral administration of 160 mg/tablet valsartan 
of both brands over the 48 h truncated sampling period.  
Time (hours)
0 1 02 03 04 05 0
V
a
l
s
a
r
t
a
n
 
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
μ
g
/
m
L
)
0
1
2
3 Valzan
Diovan
 
 
Fig. 3.   Mean plasma concentration of valsartan (± SD) of 24 volunteers versus time 
after a single oral dose administration of test tablet (160 mg valsartan, 
Pharmacare) or reference tablet (160 mg valsartan, Novartis). 
Descriptive statistics of the major mean pharmacokinetic parameters AUC0–48, AUC0–∞, 
Cmax, Tmax, Ke and T1/2 for the test and reference formulations are summarized in Table 1 
and 2. 
The relative bioavailability of valsartan from test immediate release tablet (Valzan
®,160 mg 
valsartan, Pharmacare) compared to reference immediate release tablet (Diovan
®, 160 mg 
valsartan, Novartis) was found to be 95.055%, 94.55% and 97.23% of AUC0–48, AUC0–∞ 
and Cmax respectively, and the parametric 90% confidence intervals for those 
pharmacokinetic parameters values lie entirely within the FDA specified bioequivalent limit 
(80–125%). Statistical evaluation (ANOVA) of obtained data was always carried out. 
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Tab. 2.   Pharmacokinetic parameters calculated for valsartan after a single oral dose 
administration of test tablet (160 mg valsartan, Pharmacare) to 24 healthy male 
volunteers. 
Statistical  
Parameter 
Cmax 
(µg/mL) 
Tmax 
(h) 
Ke 
(h
−1) 
T½ 
(h) 
AUC0–t 
(µg.h/mL)
AUCt-∞ 
(µg.h/mL) 
Total 
AUC0–∞ (µg.h/mL)
Mean 2.141  4.750  0.085 9.550 21.53 1.03  22.56 
S.D. 0.567  1.790  0.042 3.150 6.950 0.45    7.10 
S.E. 0.116  0.370  0.009 0.640 1.420 0.09    1.450 
Min 1.399  2.500  0.048 3.480 8.720 0.25    9.450 
Max 4.114  10.00  0.199 14.41 41.80 1.89  42.68 
 
Tab. 3.   Pharmacokinetic parameters calculated for valsartan after a single oral dose 
administration of reference tablet (160 mg valsartan, Novartis) to 24 healthy 
male volunteers. 
Statistical  
Parameter 
Cmax 
(µg/mL)
Tmax 
(h) 
Ke 
(h
−1) 
T½ 
(h) 
AUC0–t 
(µg.h/mL)
AUCt-∞ 
(µg.h/mL) 
Total 
AUC0–∞ (µg.h/mL)
Mean 2.208  4.02  0.085 9.510 22.65 1.210 23.86 
S.D. 0.663  1.44  0.044 3.030 7.860 0.530   8.040 
S.E. 0.135  0.29  0.009 0.620 1.600 0.110   1.640 
Min 0.879  2.00  0.049 3.570 6.750 0.270   7.500 
Max 3.894  8.00  0.194 14.15 41.02 2.26  42.22 
 
As above pointed out, the main objective of bioequivalence studies is to assure the 
efficacy and safety of generic formulations. Therefore, two formulations of the same drug 
are considered to be bioequivalent and per se therapeutically equivalent if they exhibit a 
comparable extent and rate of absorption, when they are administered in the same molar 
dose and under similar experimental conditions [18–20]. AUC0–∞, Cmax and Tmax values 
were statistically analyzed for determination of bioequivalence of this generic product. 
Other pharmacokinetic parameters (i.e., T1/2 and Ke) results were used as supporting 
results in this pharmacokinetic design. This study was conducted on healthy volunteers 
according to the study protocol. All subjects received the same dosages of medication, i.e 
one single dose of test formulation in the form of the test product or one single dose of 
reference in the form of the reference product with a 14 days washout period. No adverse 
events necessitating subject withdrawal from the study were reported. Statistical 
comparison of the main pharmacokinetic parameters, AUC0–48, AUC0–∞, Cmax and Tmax 
clearly indicated no significant difference between test and reference 160mg/tablet, in any 
of the calculated pharmacokinetic parameters. The obtained values were in good 
agreement with the FDA requirements for bioequivalence of generic drugs [20]. Since the 
AUC0-∞ and Cmax mean ratios are within the 80%–125% interval, it was concluded that the 
tested Valzan
® tablet (160 mg valsartan) elaborated by Pharmacare, Palestine, is 
bioequivalent for both extent and rate of absorption to the commercial Diovan
® tablet 
(160mg valsartan) manufactured by Novartis Pharma AG, Basile, Switzerland/Suiza.    Formulation and Bioequivalence of Two Valsartan Tablets After a Single Oral Administration  129 
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Conclusion 
The validated HPLC method employed here proved to be simple, fast, reliable, selective 
and sensitive enough to be used in clinical pharmacokinetic studies of valsartan in 
humans. The statistical analysis of the results of AUC0–48, AUC0–∞ and Cmax using the 
ANOVA method showed that both test immediate release tablet Valzan
® (160  mg 
valsartan, Pharmacare) and reference immediate release tablet Diovan
® (160  mg 
valsartan, Novartis) are bioequivalent, since they deliver equivalent amounts of valsartan 
to the systemic circulation at equivalent rates for both AUC0–48h and Cmax ratios within the 
80-125% interval proposed by Food and Drug Administration [20]. These results 
demonstrate that the formulation of this new generic tablet is good, an essential condition 
not only to achieve good therapeutic benefits but also to avoid any adverse effect due to 
bad formulation. Furthermore, these results are of great importance for further studies 
aimed towards the bioclassification of valsartan, since the excipients and preparation 
method of Diovan
® tablets are reported. 
Materials and Methods 
Volunteers and clinical protocol 
The study protocol and the informed consent forms were approved by the Ethical 
Committee of Tanta University Hospital (Tanta, Egypt). The whole study, which meets the 
requirements of the declarations of Helsinki, was conducted in accordance with the current 
Good Clinical Practice (GPC), International Conference Harmonization (ICH) as well as 
Good Laboratory Practice (GLP) Guidelines [21, 22]. 
Twenty-four young adult male volunteers, non smokers, aged between 18–28 years, 
weighing between 67 and 83 Kg with a mean value of 76.25 ± 5.64Kg, were chosen to 
participate in the present study. The volunteers were not on concomitant medications and 
they were free from significant cardiac, hepatic, renal, pulmonary, gastrointestinal, 
neurological or hematological disease as determined within four weeks prior to the 
beginning of the study by way of medical histories and physical examinations. Subject’s 
health status was determined following a physical examination, laboratory tests and 
medical history by a qualified registered MD physician. The physician reviewed all 
preclinical laboratory tests for each subject. Tests included the following: (i) physical 
examination: height, weight, blood pressure, heart rate, body temperature and respiratory 
rate; (ii) blood chemistry: glucose, uric acid, BUN, creatinine AST, ALT, cholesterol and 
triglycerides; (iii) hematological tests: hemoglobin, hematocrit, ESR, WBCs with 
differential, RBCs with platelets count and morphology, lymphocytes, MCV, MCH, 
monocytes, neutrophils, eosinophils, basophils, HIV and Hepatitis B screen; (iv) urine 
analysis:  specific gravity, pH and microscopic examination. These clinical tests were 
performed in order to determine if they fitted with the participation in the study. Exclusion 
criteria included extreme weight ranges (overweight or underweight), anemia, liver or renal 
dysfunction, parasitic and other diseases or conditions that was judged to affect the 
absorption, distribution and/or elimination of valsartan. All volunteers were given a written 
informed consent, which explained the nature of the study. All volunteers were interested 
and willing to participate in the study. The subjects were asked to abstain from taking 
drugs and alcohol for at least 3 days prior to the study and throughout the study period. On 
the night before starting the study, the volunteers were instructed to fast for at least 10 h 130  A. N. Zaid et al.:  
Sci Pharm. 2011; 79: 123–135 
before drug administration. The study had an open randomized two-period crossover 
design with a 14-day washout period between doses. The volunteers were arbitrarily 
divided into two equal groups each of 12 subjects. To the first group the reference 
formulation was given and to the second group the test formulation was given with a 
crossover after a washout period of two weeks. On the morning of the experiment, a blood 
sample was withdrawn from each volunteer to serve as a blank for the drug assay. Each of 
the 24 volunteers then took one Valzan
® 160 mg per tablet as the test drug, or one 
Diovan
®160 mg per tablet as the reference drug followed by 240 ml of water. Blood 
samples for plasma drug assay were collected from an indwelling catheter inserted in the 
antecubital vein of one of the arms. Samples were obtained at 0.0, 0.25, 0.5, 0.75, 1, 1.5, 
2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 48 h after drug administration, in heparinized tubes. 
Plasma was directly separated by centrifugation at 3000 rpm for 10 min, removed out and 
stored at −20°C until assayed. Four hours after drug administration, the subjects were 
allowed to eat a standard breakfast of bread, jam, potato, low-fat white cheese and water 
(150 ml). They were then allowed controlled access to water and other non-alcoholic 
beverages. The volunteers had their second meal (standard lunch containing grilled 
chicken, rice and vegetables) 4 h later. It should be noted that valsartan is rapidly 
absorbed from gastrointestinal tract after oral administration and can be administered 
without regard to food intake. The peak effect of valsartan is evident in 2–4 h; the 
bioavailability is 25% [23]. The maximum plasma concentrations after single oral dose of 
valsartan (160 mg) reached 4 µg/mL [8].  
Drugs and chemicals 
Acetonitrile (ACN) and methanol (MeOH) were purchased from Merck, (Darmstadt, 
Germany); ammonium dihydrogen ortho phosphate was purchased from Riedel-de Haën 
(Seelze, Germany); acetic acid and diethyl ether (ADS, France), Hexan sulfonic acid 
sodium (PXPARK Scientific Limited, UK) and double distilled high purity water was used. 
Human plasma was harvested from donors. The HPLC grade solvents ACN and MeOH 
were used as received. All other reagents were analytical grade. Valsartan (batch number 
VS0060307, expiration date 11/2013) and etodolac (batch number CAS 1938 internal 
standard) were supplied by Pharmacare, Chemical & Cosmetics, Ramallah, Palestine). All 
experiments were carried out before April 2009. 
Formulations 
The following test formulation was employed: Valzan
® tablet (160 mg valsartan /tablet) 
from Pharmacare Chemical & Cosmetics, Ramallah, Palestine, (batch number RD-09B09; 
Expiry date 02/2011). The reference formulation was Diovan
® tablet (160 mg 
valsartan/tablet) manufactured by Novartis Pharma AG, Basile, Switzerland/Suiza, (batch 
number 21234; Expiry date 11/7/2011). Valzan
® was prepared according to a dry 
granulation method (roll compaction). Tablet formulation contained the following inactive 
ingredients: lactose, avicel, HPMC, aerosol, magnesium stearate, plasdone, talc, yellow 
iron oxide, red iron oxide, and titanium dioxide. The in-vitro release of the valsartan from 
Valzan
® was within the acceptable level reported by the profile for valsartan. The release 
of Diovan and Valzan were more than 85% after 15 min, this means that no need to 
perform the similarity and dissimilarity factors (F2 or F1). The test was carried out 
according to the USP 30 specifications. The tablets were placed in the vessels of the 
dissolution apparatus containing 1000 mL of a phosphate buffer with pH 6.8. Rotation was 
set on 100 rpm using USP apparatus I (Basket type) “Vailidata” hanson Research SR6.   Formulation and Bioequivalence of Two Valsartan Tablets After a Single Oral Administration  131 
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Temperature was maintained at 37°C during the time of dissolution test of 120 min. The 
tablets were placed in the vessels. Samples (5 ml) were taken at 1, 2, 3, 4, 5, 10, 15, 20, 
30, 45, 60, 90 and 120 min. These samples were filtered through a Millipore filter 0.45µm 
before dilution with phosphate buffer. 25 µL of sample solutions were injected in the HPLC. 
Instruments and chromatographic conditions 
The HPLC system Model LC-10 VP, (Shimadzu Scientific Instruments) was employed. 
Separation was accomplished with a 250 mm X 4.6 mm, 5μm Hypersil
® BDS C18 column. 
The mobile phase involved a mixture of 20 mM ammonium dihydrogen phosphate buffer 
(pH adjusted to 3.2 with phosphoric acid): acetonitrile (40:60, v/v), pumped at a flow rate of 
1.7 mL/min. RF-10A XL Shimadzu fluorescence detector was set at 255 nm for excitation 
and 370 nm for emission. The peak quantification of valsartan was obtained by plotting 
valsartan to internal standard peak area ratios as a function of concentration. Areas were 
calculated utilizing the data analysis program Class-VP (Shimadzu Scientific Instruments).  
Standard solutions 
Stock solution of valsartan (100 μg/mL) was prepared by dissolving 10 mg of valsartan in 
100 mL methanol. Working standard solutions were prepared from the stock solution by 
sequential dilution with methanol to prepare ten working solutions of valsartan with 
concentrations of 100, 50, 20, 10, 5.0, 2.0, 1.0, 0.5, 0.2, 0.1 μg/mL. Stock solution of 
etodolac (internal standard) was prepared by dissolving 2.0 mg etodolac powder in 100 mL 
MeOH (20 μg/mL). Twenty- five (25) μL from each working standard solution, and the 
internal standard solution were transferred to a set of clean test tubes, 25 µL of blank 
plasma was added after evaporation and vortexed. Then treated with 0.5 mL of methanol 
and shaked for 30 sec, then centrifuged at 3000 rpm for 7 min. The supernatant was 
transferred to clean HPLC vials and 25 µL were injected into the HPLC column. Stock and 
working standard solutions were protected from light and stored at −20°C until use.  
Preparation of calibration standards 
The calibration standards were prepared by adding known amounts (25 µL) from each 
working solution, and 25 μL of the internal standard solution to a set of clean test tubes. 
After evaporation of the methanolic solution, 0.25 mL of blank plasma was added to each 
tube to form a set of calibration standards with concentrations of 10, 5, 2, 1, 0.5, 0.2, 0.1, 
0.05, 0.02, 0.01 µg/ mL.  
Sample preparations for HPLC injection 
25 μL of each study sample was transferred to a clean test tube. The study samples were 
treated as the calibration standards after addition of the internal standard.  
Validation Procedures 
The validation of this chromatographic analytical method was performed in order to 
evaluate its linearity, selectivity, stability, precision and accuracy. 
Calibration curves were constructed from the peak area ratio (drug/ internal standard) and 
the corresponding valsartan concentration in each calibration standard. The linearity study 
was carried out in the concentration range of 0.01 to 10 µg/mL. To assess linearity, drug 132  A. N. Zaid et al.:  
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free plasma was spiked with known amounts of the drug to achieve the concentration of 
0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1.0, 2.0, 5.0, and 10 µg/mL.  
Precision was determined as the coefficient of variation (%CV), and the accuracy as the 
percentage relative error (RE) of a series of measurements. Precision and accuracy data 
were obtained by analyzing aliquots of three spiked plasma samples at low middle and 
high concentration levels of valsartan. Intra-day reproducibility was determined by 
analyzing three replicates of calibration curves on the same day, and inter-day 
reproducibility was evaluated by the analysis of six different calibration curves on six 
different days during the study period.  
The stability of the drug at room temperature was determined by preparing three different 
plasma samples for each drug concentration and then injecting the samples immediately 
into the HPLC system. The samples were kept at room temperature and were injected 
again after 24 h. The concentrations measured at time zero and after 24 h were compared 
to determine whether there were changes in the concentrations with time.  
The stability of the drug in frozen plasma was investigated by the analysis of the study 
samples obtained from three volunteers twice. The first analysis was performed at the 
beginning of the study and the second analysis was performed at the end of the study. The 
samples were stored at −20°C between the analyses. The low limit of quantification 
(LLOQ) is defined as the lowest concentration of analyte that can be determined with 
acceptable precision and accuracy under the stated experimental conditions. The LLOQ 
was estimated by analyzing samples with known amounts of valsartan, at progressively 
lower concentrations, starting at the lower end of the calibration curves. The performance 
of the assay during the analysis of the study samples was evaluated by the analysis of the 
quality control (QC) samples. The QC samples were prepared by spiking blank plasma 
with valsartan before the beginning of the study sample analysis. The QC samples were 
prepared to have low, medium and high valsartan concentrations (0.05, 1.0 and 5.0 
μg/mL). Three QC samples were incorporated with each analysis run and were treated as 
unknown samples. The concentration in each QC sample was determined from the 
calibration curve and the calculated concentration was compared with the nominal 
concentration. The analysis run was accepted if at least 2 out of 3 QC samples were within 
20% of nominal concentration [24]. 
An incurred sample reanalysis (ISR) was performed on 72 sample from all study subjects. 
Three sample points for each study period were selected and reanalyzed to test the 
reproducibility of the assay [25]. 
Pharmacokinetic and statistical analysis  
The maximum valsartan plasma concentration (Cmax) and the corresponding time of peak 
plasma concentration (Tmax) were taken directly from the slope of the semi-logarithmic plot 
of the terminal phase of the plasma concentration-time curve calculated by linear 
regression. The elimination half–life (T1/2) was derived by dividing ln2 by the elimination 
rate constant Ke. The areas under the valsartan plasma concentrations time curves from 
(AUC0–48) and the area to the infinity (AUC0–∞) were calculated by using the linear 
trapezoidal method. Extrapolation to the infinity was done by adding the value Ct/Ke to the 
calculated AUC0–48 (where Ct is the last detectable concentration of valsartan). For the   Formulation and Bioequivalence of Two Valsartan Tablets After a Single Oral Administration  133 
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purpose of bioequivalence analysis, one way analysis of variance (ANOVA procedure) 
was used to assess the effect of formulations, periods, sequences and subjects on   
AUC0–48, AUC0–∞, and Cmax. 
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